Biomea Fusion Highlights Recent Updates and Anticipated
Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion ...
Read moreExpansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion ...
Read moreArtemish, the epitome of luxury and craftsmanship in the furniture industry, proudly announces its exclusive sponsorship at the renowned ...
Read moreBengaluru, Karnataka, India Bengaluru-based brand Que by M - well-known for affordable millennial jewellery is foraying into the Active ...
Read moreAt Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients ...
Read moreBMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes ...
Read moreMESA, Ariz.--(BUSINESS WIRE)--Fusion Orthopedics, LLC announced today that the USPTO’s Patent Trial and Appeal Board (“PTAB”) has ruled against Extremity ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.